{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:47:27Z","timestamp":1793713647719,"version":"4.6.1"},"reference-count":45,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,2,21]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1\u2013, E2b\u2013] targeting three TAAs\u2014prostate-specific antigen (PSA), brachyury, and MUC-1\u2014has been developed. Both brachyury and the C-terminus of MUC-1 are overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and have been shown to play an important role in resistance to chemotherapy, epithelial\u2013mesenchymal transition, and metastasis. The transgenes for PSA, brachyury, and MUC-1 all contain epitope modifications for the expression of CD8+ T-cell enhancer agonist epitopes. We report here the first-in-human trial of this vaccine platform.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with mCRPC were given concurrently three vaccines targeting PSA, brachyury, and MUC-1 at 5\u00d710<jats:sup>11<\/jats:sup> viral particles (VP) each, subcutaneously every 3 weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every 8 weeks for 1\u2009year (dose-expansion cohort only). The primary objective was to determine the safety and the recommended phase II dose. Immune assays and clinical responses were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighteen patients with mCRPC were enrolled between July 2018 and September 2019 and received at least one vaccination. Median PSA was 25.58\u2009ng\/mL (range, 0.65\u20131006 ng\/mL). The vaccine was tolerable and safe, and no grade &gt;3 treatment-related adverse events or dose-limiting toxicities (DLTs) were observed. One patient had a partial response, while five patients had confirmed PSA decline and five had stable disease for &gt;6 months. Median progression-free survival was 22 weeks (95%\u2009CI: 19.1 to 34). Seventeen (100%) of 17 patients mounted T-cell responses to at least one TAA, whereras 8 (47%) of 17 patients mounted immune responses to all three TAAs. Multifunctional T-cell responses to PSA, MUC-1, and brachyury were also detected after vaccination in the majority of the patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ad5 PSA\/MUC-1\/brachyury vaccine is well tolerated. The primary end points were met and there were no DLTs. The recommended phase II dose is 5\u00d710<jats:sup>11<\/jats:sup>\u2009VP. The vaccine demonstrated clinical activity, including one partial response and confirmed PSA responses in five patients. Three patients with prolonged PSA responses received palliative radiation therapy. Further research is needed to evaluate the clinical benefit and immunogenicity of this vaccine in combination with other immuno-oncology agents and\/or palliative radiation therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03481816\">NCT03481816<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-002374","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T12:42:58Z","timestamp":1616589778000},"page":"e002374","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03481816","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01147965","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00001846","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03481816","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-689X","authenticated-orcid":false,"given":"Marijo","family":"Bilusic","sequence":"first","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"McMahon","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-1332","authenticated-orcid":false,"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo-Ting","family":"Tsai","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee N","family":"Donahue","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Palena","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-9855","authenticated-orcid":false,"given":"Caroline","family":"Jochems","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Mart\u00e9","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-237X","authenticated-orcid":false,"given":"Charalampos","family":"Floudas","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Strauss","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Redman","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-3726","authenticated-orcid":false,"given":"Houssein","family":"Abdul Sater","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrooz","family":"Rabizadeh","sequence":"additional","affiliation":[{"name":"ImmunityBio, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Soon-Shiong","sequence":"additional","affiliation":[{"name":"ImmunityBio, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"2025100314121385000_9.3.e002374.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.05.021"},{"key":"2025100314121385000_9.3.e002374.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12645-015-0010-5","article-title":"Dna vaccination for prostate cancer: key concepts and considerations","volume":"6","author":"Cole","year":"2015","journal-title":"Cancer Nanotechnol"},{"key":"2025100314121385000_9.3.e002374.3","first-page":"40","article-title":"Prostate tumor biology and cell kinetics--theory","volume":"17","author":"Coffey","year":"1981","journal-title":"Urology"},{"key":"2025100314121385000_9.3.e002374.4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100314121385000_9.3.e002374.5","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00032-V"},{"key":"2025100314121385000_9.3.e002374.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.013"},{"key":"2025100314121385000_9.3.e002374.7","first-page":"1","article-title":"New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations","volume":"2012","author":"Gabitzsch","year":"2012","journal-title":"J Clin Cellular Immunol"},{"key":"2025100314121385000_9.3.e002374.8","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.17"},{"key":"2025100314121385000_9.3.e002374.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.11.003"},{"key":"2025100314121385000_9.3.e002374.10","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1016\/j.vaccine.2011.08.038","article-title":"Induction and comparison of SIV immunity in Ad5 na\u00efve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine","volume":"29","author":"Gabitzsch","year":"2011","journal-title":"Vaccine"},{"key":"2025100314121385000_9.3.e002374.11","doi-asserted-by":"crossref","first-page":"31344","DOI":"10.18632\/oncotarget.5181","article-title":"The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"2025100314121385000_9.3.e002374.12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA\/MUC1\/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"2025100314121385000_9.3.e002374.13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00262-015-1706-4","article-title":"Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer","volume":"64","author":"Balint","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2025100314121385000_9.3.e002374.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70006-2"},{"key":"2025100314121385000_9.3.e002374.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1087"},{"key":"2025100314121385000_9.3.e002374.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1400-3"},{"key":"2025100314121385000_9.3.e002374.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0847-8"},{"key":"2025100314121385000_9.3.e002374.18","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.82"},{"key":"2025100314121385000_9.3.e002374.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0183"},{"key":"2025100314121385000_9.3.e002374.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300022"},{"key":"2025100314121385000_9.3.e002374.21","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22546"},{"key":"2025100314121385000_9.3.e002374.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-427799"},{"key":"2025100314121385000_9.3.e002374.23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1067745"},{"key":"2025100314121385000_9.3.e002374.24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629"},{"key":"2025100314121385000_9.3.e002374.25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semradonc.2014.07.002","article-title":"Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities","volume":"25","author":"Garnett-Benson","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"2025100314121385000_9.3.e002374.26","first-page":"289","article-title":"Silvia Formenti on the promise of combining radiotherapy and immunotherapy to treat cancer","volume":"30","author":"Formenti","year":"2016","journal-title":"Oncology"},{"key":"2025100314121385000_9.3.e002374.27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-Induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"2025100314121385000_9.3.e002374.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6338"},{"key":"2025100314121385000_9.3.e002374.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5239.1189"},{"key":"2025100314121385000_9.3.e002374.30","doi-asserted-by":"publisher","DOI":"10.1385\/MB:25:1:19"},{"key":"2025100314121385000_9.3.e002374.31","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28643"},{"key":"2025100314121385000_9.3.e002374.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025100314121385000_9.3.e002374.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1251"},{"key":"2025100314121385000_9.3.e002374.34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4161\/cbt.8.13.8844","article-title":"Functional targeting of the MUC1 oncogene in human cancers","volume":"8","author":"Kufe","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"2025100314121385000_9.3.e002374.35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1947601911405044","article-title":"Muc1-C oncoprotein blocks terminal differentiation of chronic myelogenous leukemia cells by a ROS-mediated mechanism","volume":"2","author":"Yin","year":"2011","journal-title":"Genes Cancer"},{"key":"2025100314121385000_9.3.e002374.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3211"},{"key":"2025100314121385000_9.3.e002374.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.11.015"},{"key":"2025100314121385000_9.3.e002374.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0421"},{"key":"2025100314121385000_9.3.e002374.39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju054","article-title":"Overexpression of the EMT driver Brachyury in breast carcinomas: association with poor prognosis","volume":"106","author":"Palena","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025100314121385000_9.3.e002374.40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1245\/s10434-013-2914-9","article-title":"Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma","volume":"20 Suppl 3","author":"Haro","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2025100314121385000_9.3.e002374.41","doi-asserted-by":"crossref","first-page":"83115","DOI":"10.18632\/oncotarget.13073","article-title":"Amplification of MUC1 in prostate cancer metastasis and CRPC development","volume":"7","author":"Wong","year":"2016","journal-title":"Oncotarget"},{"key":"2025100314121385000_9.3.e002374.42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1634\/theoncologist.2019-0932","article-title":"Phase I trial of a modified vaccinia Ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express Brachyury and costimulatory molecules in advanced solid tumors","volume":"25","author":"Collins","year":"2020","journal-title":"Oncologist"},{"key":"2025100314121385000_9.3.e002374.43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0119"},{"key":"2025100314121385000_9.3.e002374.44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00262-016-1893-7","article-title":"A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-\u03b1-2b in patients with CEA-expressing carcinomas","volume":"65","author":"Duggan","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2025100314121385000_9.3.e002374.45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000655"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:12:25Z","timestamp":1759525945000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,24]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2021-002374"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002374","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}